Lee Y R, Oshita Y, Tsuboi R, Ogawa H
Department of Dermatology, Juntendo University School of Medicine, Tokyo, Japan.
Endocrinology. 1996 Dec;137(12):5278-83. doi: 10.1210/endo.137.12.8940346.
Wound contraction is an important event that minimizes the wound defect during the healing process. Involvement of insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP)-1 in wound contraction was studied using an in vitro model. Human dermal fibroblasts (1 x 10(5) cells/ml) were incorporated into a porcine type I collagen (0.21% final) in serum-free medium. The fibroblast-embedded collagen gels in a 12-well plate were floated from the well, and various reagents were then added to the assay medium. The surface area of the gel was calculated by measuring the diameters of the collagen gel. IGF-I at high doses (30 and 100 ng/ml) revealed 6.8% (P < 0.01) and 7.7% (P < 0.001) gel contraction, respectively, and des (1-3) IGF-I at 10 ng/ml produced a 4.5% gel contraction (P < 0.01). Meanwhile, IGFBP-I did not induce any significant contraction throughout the tested concentrations (0.1-100 ng/ml). A combination of IGF-I and IGFBP-1 at 1 ng/ml of each reagent, a concentration at which gel contraction was not observed when each of the reagents was tested individually, produced a 14% gel contraction (P < 0.001), whereas combinations of des (1-3) IGF-I with IGFBP-1 at the same concentrations did not promote gel contraction. The increased IGFBP-I doses in combination with 1 ng/ml IGF-I tended to enhance the gel contraction. IGF-I- and IGFBP-1-induced gel contraction was prominent during the initial 12-h incubation period. When anti-IGF-I, anti-IGFBP-1, or anti-IGF-I receptor antibody was added to the assay medium before the addition of IGF-I and IGFBP-1, the IGF-I- and IGFBP-1-induced gel contraction was significantly suppressed (P < 0.001). Endothelin-1, a vasoconstrictor peptide that is known to promote fibroblast-embedded collagen gel contraction, appeared to be partially involved in the IGF-I- and IGFBP-1-induced gel contraction, because the addition of an endothelin receptor antagonist (Bosentan or BE-18257B at 1 microg/ml) moderately suppressed the IGF-I- and IGFBP-1-induced gel contraction (P < 0.01). On the other hand, when IGF-I and IGFBP-1 were applied with endothelin-1 (1 nM), an enhanced gel contraction (29.4%) was observed that was significantly greater than that induced by either individually (P < 0.001). These results clearly indicate that the combination of IGF-I and IGFBP-1 promotes fibroblast contraction in collagen gel, and that this phenomenon is caused by IGFBP-1's strong potentiation of the IGF-I-induced gel contraction.
伤口收缩是愈合过程中使伤口缺损最小化的重要事件。使用体外模型研究了胰岛素样生长因子(IGF)-I和IGF结合蛋白(IGFBP)-1在伤口收缩中的作用。将人真皮成纤维细胞(1×10⁵个细胞/毫升)加入无血清培养基中的猪I型胶原蛋白(终浓度0.21%)中。将12孔板中包埋有成纤维细胞的胶原凝胶从孔中漂浮起来,然后向测定培养基中加入各种试剂。通过测量胶原凝胶的直径计算凝胶的表面积。高剂量(30和100纳克/毫升)的IGF-I分别使凝胶收缩6.8%(P<0.01)和7.7%(P<0.001),10纳克/毫升的脱(1-3)IGF-I使凝胶收缩4.5%(P<0.01)。同时,在整个测试浓度(0.1-100纳克/毫升)范围内,IGFBP-1未诱导任何显著的收缩。每种试剂浓度为1纳克/毫升时,单独测试时未观察到凝胶收缩,但IGF-I与IGFBP-1组合可使凝胶收缩14%(P<0.001),而相同浓度下脱(1-3)IGF-I与IGFBP-1组合则不促进凝胶收缩。与1纳克/毫升IGF-I联合使用时,IGFBP-1剂量增加倾向于增强凝胶收缩。IGF-I和IGFBP-1诱导的凝胶收缩在最初12小时孵育期内最为显著。在加入IGF-I和IGFBP-1之前,向测定培养基中加入抗IGF-I、抗IGFBP-1或抗IGF-I受体抗体,可显著抑制IGF-I和IGFBP-1诱导的凝胶收缩(P<0.001)。内皮素-1是一种已知可促进包埋有成纤维细胞的胶原凝胶收缩的血管收缩肽,似乎部分参与了IGF-I和IGFBP-1诱导的凝胶收缩,因为加入内皮素受体拮抗剂(1微克/毫升的波生坦或BE-18257B)可适度抑制IGF-I和IGFBP-1诱导的凝胶收缩(P<0.01)。另一方面,当IGF-I和IGFBP-1与内皮素-1(1纳摩尔)一起应用时,观察到凝胶收缩增强(29.4%),显著大于单独使用时的收缩(P<0.001)。这些结果清楚地表明,IGF-I和IGFBP-1的组合促进胶原凝胶中成纤维细胞的收缩,并且这种现象是由IGFBP-1对IGF-I诱导的凝胶收缩的强烈增强作用引起的。